Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>

Common stock purchase or sale:
Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
2021-10-27 Sale |
2021-10-28 7:25 pm |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
800 | $35.25 | $28,200 | 104,952 (Direct) |
View |
2021-10-27 Sale |
2021-10-28 7:23 pm |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
400 | $35 | $14,000 | 82,863 (Direct) |
View |
2021-10-11 Sale |
2021-10-12 6:43 pm |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
1,200 | $27.36 | $32,832 | 105,752 (Direct) |
View |
2021-10-01 Sale |
2021-10-04 5:16 pm |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
400 | $29.92 | $11,968 | 83,263 (Direct) |
View |
2021-09-10 Sale |
2021-09-13 4:07 pm |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
2,000 | $35.93 | $71,860 | 106,952 (Direct) |
View |
2021-09-07 Sale |
2021-09-08 5:08 pm |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
3,200 | $35.25 | $112,800 | 108,952 (Direct) |
View |
2021-09-07 Sale |
2021-09-08 5:08 pm |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
1,600 | $35 | $56,000 | 83,663 (Direct) |
View |
2021-09-01 Sale |
2021-09-02 4:22 pm |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
400 | $32.34 | $12,936 | 85,263 (Direct) |
View |
2021-08-10 Sale |
2021-08-11 6:21 pm |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
1,200 | $29.87 | $35,845 | 111,671 (Direct) |
View |
2021-08-10 Sale |
2021-08-11 6:20 pm |
Nurix Therapeutics Inc. | NRIX | Beaurang Pierre Chief Business Officer |
7,500 | $29.86 | $223,926 | 127,558 (Indirect Direct) |
View |
2021-08-02 Sale |
2021-08-03 5:39 pm |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
400 | $31.21 | $12,484 | 85,270 (Direct) |
View |
2021-07-20 Sale |
2021-07-21 5:34 pm |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
1,200 | $27 | $32,400 | 112,871 (Direct) |
View |
2021-07-12 Sale |
2021-07-12 7:36 pm |
Nurix Therapeutics Inc. | NRIX | Beaurang Pierre Chief Business Officer |
7,500 | $23.92 | $179,419 | 135,058 (Indirect Direct) |
View |
2021-07-01 Sale |
2021-07-02 4:03 pm |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
400 | $26.76 | $10,704 | 85,670 (Direct) |
View |
2021-06-10 Sale |
2021-06-11 4:11 pm |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
1,200 | $29.4 | $35,282 | 114,071 (Direct) |
View |
2021-06-10 Sale |
2021-06-11 4:10 pm |
Nurix Therapeutics Inc. | NRIX | Beaurang Pierre Chief Business Officer |
7,500 | $29.37 | $220,248 | 142,558 (Indirect Direct) |
View |
2021-06-01 Sale |
2021-06-02 4:49 pm |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
400 | $27.74 | $11,096 | 86,070 (Direct) |
View |
2021-05-10 Sale |
2021-05-11 7:58 pm |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
1,200 | $27 | $32,400 | 115,271 (Direct) |
View |
2021-05-10 Sale |
2021-05-11 7:56 pm |
Nurix Therapeutics Inc. | NRIX | Beaurang Pierre Chief Business Officer |
7,500 | $26.49 | $198,644 | 150,058 (Indirect Direct) |
View |
2021-05-03 Sale |
2021-05-04 4:27 pm |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
800 | $34.99 | $27,996 | 86,470 (Direct) |
View |
2021-04-28 Sale |
2021-04-29 6:05 pm |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
800 | $35.25 | $28,200 | 116,471 (Direct) |
View |
2021-04-12 Sale |
2021-04-13 5:20 pm |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
1,200 | $27.2 | $32,640 | 117,271 (Direct) |
View |
2021-04-12 Sale |
2021-04-13 5:19 pm |
Nurix Therapeutics Inc. | NRIX | Beaurang Pierre Chief Business Officer |
7,500 | $27.28 | $204,632 | 157,558 (Indirect Direct) |
View |
2021-04-05 Sale |
2021-04-06 4:04 pm |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
400 | $35 | $14,000 | 87,270 (Direct) |
View |
2021-04-01 Sale |
2021-04-02 5:22 pm |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
400 | $31.55 | $12,620 | 87,670 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
2021-10-27 Exercise |
2021-10-28 7:25 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
800 | $1.86 | 104,952 (Direct) |
View |
2021-10-27 Exercise |
2021-10-28 7:25 pm |
N/A 2029-09-30 |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
800 | $0 | 104,952 (Direct) |
View |
2021-10-27 Exercise |
2021-10-28 7:23 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
400 | $7.26 | 82,863 (Direct) |
View |
2021-10-27 Exercise |
2021-10-28 7:23 pm |
N/A 2030-02-26 |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
400 | $0 | 82,863 (Direct) |
View |
2021-10-11 Exercise |
2021-10-12 6:43 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
1,200 | $1.86 | 105,752 (Direct) |
View |
2021-10-11 Exercise |
2021-10-12 6:43 pm |
N/A 2029-09-30 |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
1,200 | $0 | 105,752 (Direct) |
View |
2021-10-01 Exercise |
2021-10-04 5:16 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
400 | $7.26 | 83,263 (Direct) |
View |
2021-10-01 Exercise |
2021-10-04 5:16 pm |
N/A 2030-02-26 |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
400 | $0 | 83,263 (Direct) |
View |
2021-10-01 Option Award |
2021-10-04 5:16 pm |
N/A 2031-09-30 |
Nurix Therapeutics Inc. | NRIX | Reinsdorf Judith A Director |
35,000 | $0 | 35,000 (Direct) |
View |
2021-10-01 Option Award |
2021-10-04 5:15 pm |
N/A 2031-09-30 |
Nurix Therapeutics Inc. | NRIX | Silva Paul M Director |
35,000 | $0 | 35,000 (Direct) |
View |
2021-09-10 Exercise |
2021-09-13 4:07 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
2,000 | $1.86 | 106,952 (Direct) |
View |
2021-09-10 Exercise |
2021-09-13 4:07 pm |
N/A 2029-09-30 |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
2,000 | $0 | 106,952 (Direct) |
View |
2021-09-07 Exercise |
2021-09-08 5:08 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
3,200 | $1.86 | 108,952 (Direct) |
View |
2021-09-07 Exercise |
2021-09-08 5:08 pm |
N/A 2029-09-30 |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
3,200 | $0 | 108,952 (Direct) |
View |
2021-09-07 Exercise |
2021-09-08 5:08 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
1,600 | $7.26 | 83,663 (Direct) |
View |
2021-09-07 Exercise |
2021-09-08 5:08 pm |
N/A 2030-02-26 |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
1,600 | $0 | 83,663 (Direct) |
View |
2021-09-01 Exercise |
2021-09-02 4:22 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
400 | $7.26 | 85,263 (Direct) |
View |
2021-09-01 Exercise |
2021-09-02 4:22 pm |
N/A 2030-02-26 |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
400 | $0 | 85,263 (Direct) |
View |
Ownership |
2021-08-17 5:19 pm |
N/A 2031-07-12 |
Nurix Therapeutics Inc. | NRIX | Wolff Stefani EVP and COO |
0 | $0 | 443,865 (Direct) |
View |
2021-08-10 Exercise |
2021-08-11 6:21 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
1,200 | $1.86 | 111,671 (Direct) |
View |
2021-08-10 Exercise |
2021-08-11 6:21 pm |
N/A 2029-09-30 |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
1,200 | $0 | 111,671 (Direct) |
View |
2021-08-10 Exercise |
2021-08-11 6:20 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Beaurang Pierre Chief Business Officer |
7,500 | $1.11 | 127,558 (Direct) |
View |
2021-08-10 Exercise |
2021-08-11 6:20 pm |
N/A 2027-02-01 |
Nurix Therapeutics Inc. | NRIX | Beaurang Pierre Chief Business Officer |
7,500 | $0 | 127,558 (Direct) |
View |
2021-08-02 Exercise |
2021-08-03 5:39 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
400 | $7.26 | 85,270 (Direct) |
View |
2021-08-02 Exercise |
2021-08-03 5:39 pm |
N/A 2030-02-26 |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
400 | $0 | 85,270 (Direct) |
View |
2021-07-20 Exercise |
2021-07-21 5:34 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
1,200 | $1.86 | 112,871 (Direct) |
View |
2021-07-20 Exercise |
2021-07-21 5:34 pm |
N/A 2029-09-30 |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
1,200 | $0 | 112,871 (Direct) |
View |
2021-07-12 Exercise |
2021-07-12 7:36 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Beaurang Pierre Chief Business Officer |
7,500 | $1.11 | 135,058 (Direct) |
View |
2021-07-12 Exercise |
2021-07-12 7:36 pm |
N/A 2027-02-01 |
Nurix Therapeutics Inc. | NRIX | Beaurang Pierre Chief Business Officer |
7,500 | $0 | 135,058 (Direct) |
View |
2021-07-01 Exercise |
2021-07-02 4:03 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
400 | $7.26 | 85,670 (Direct) |
View |
2021-07-01 Exercise |
2021-07-02 4:03 pm |
N/A 2030-02-26 |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
400 | $0 | 85,670 (Direct) |
View |
2021-06-10 Exercise |
2021-06-11 4:11 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
1,200 | $1.86 | 114,071 (Direct) |
View |
2021-06-10 Exercise |
2021-06-11 4:11 pm |
N/A 2029-09-30 |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
1,200 | $0 | 114,071 (Direct) |
View |
2021-06-10 Exercise |
2021-06-11 4:10 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Beaurang Pierre Chief Business Officer |
7,500 | $1.11 | 142,558 (Direct) |
View |
2021-06-10 Exercise |
2021-06-11 4:10 pm |
N/A 2027-02-01 |
Nurix Therapeutics Inc. | NRIX | Beaurang Pierre Chief Business Officer |
7,500 | $0 | 142,558 (Direct) |
View |
2021-06-01 Exercise |
2021-06-02 4:49 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
400 | $7.26 | 86,070 (Direct) |
View |
2021-06-01 Exercise |
2021-06-02 4:49 pm |
N/A 2030-02-26 |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
400 | $0 | 86,070 (Direct) |
View |
2021-05-28 Option Award |
2021-06-01 4:21 pm |
N/A 2031-05-27 |
Nurix Therapeutics Inc. | NRIX | SIEGALL CLAY B Director |
35,000 | $0 | 35,000 (Direct) |
View |
2021-05-06 Option Award |
2021-05-24 7:50 pm |
N/A 2031-05-05 |
Nurix Therapeutics Inc. | NRIX | Tong Jeffrey K Director 10% Owner |
17,500 | $0 | 17,500 (Direct) |
View |
2021-05-06 Option Award |
2021-05-24 7:49 pm |
N/A 2031-05-05 |
Nurix Therapeutics Inc. | NRIX | Lacey David L. Director |
17,500 | $0 | 17,500 (Direct) |
View |
2021-05-06 Option Award |
2021-05-24 7:49 pm |
N/A 2031-05-05 |
Nurix Therapeutics Inc. | NRIX | Kunkel Lori Anne Director |
17,500 | $0 | 17,500 (Direct) |
View |
2021-05-06 Option Award |
2021-05-24 7:48 pm |
N/A 2031-05-05 |
Nurix Therapeutics Inc. | NRIX | GREGORY JULIA P Director |
17,500 | $0 | 17,500 (Direct) |
View |
2021-05-06 Option Award |
2021-05-24 7:48 pm |
N/A 2031-05-05 |
Nurix Therapeutics Inc. | NRIX | Chen Leon Director |
17,500 | $0 | 17,500 (Direct) |
View |
2021-05-10 Exercise |
2021-05-11 7:58 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
1,200 | $1.86 | 115,271 (Direct) |
View |
2021-05-10 Exercise |
2021-05-11 7:58 pm |
N/A 2029-09-30 |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
1,200 | $0 | 115,271 (Direct) |
View |
2021-05-10 Exercise |
2021-05-11 7:56 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Beaurang Pierre Chief Business Officer |
7,500 | $1.11 | 150,058 (Direct) |
View |
2021-05-10 Exercise |
2021-05-11 7:56 pm |
N/A 2027-02-01 |
Nurix Therapeutics Inc. | NRIX | Beaurang Pierre Chief Business Officer |
7,500 | $0 | 150,058 (Direct) |
View |
2021-05-06 Other |
2021-05-10 4:41 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Third Rock Ventures III L.P. Third Rock Ventures GP III L.P. TRV GP III LLC STARR KEVIN P TEPPER ROBERT I LEVIN MARK J 10% Owner |
1,085,784 | $0 | 4,768,725 (Direct) |
View |
2021-05-05 Other |
2021-05-07 8:50 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | COLUMN GROUP L P Svennilson Peter 10% Owner |
3,771,383 | $0 | 7,113,140 (Direct) |
View |
2021-05-05 Other |
2021-05-07 8:40 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | COLUMN GROUP L P COLUMN GROUP GP LP COLUMN GROUP II LP Column Group II GP LP PONOI CAPITAL LP Ponoi Management LLC Ponoi II Management LLC Ponoi Capital II LP Kutzkey Tim GOEDDEL DAVID V 10% Owner |
3,771,383 | $0 | 7,113,140 (Direct) |
View |
2021-05-03 Exercise |
2021-05-04 4:27 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
800 | $7.26 | 86,470 (Direct) |
View |
2021-05-03 Exercise |
2021-05-04 4:27 pm |
N/A 2030-02-26 |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
800 | $0 | 86,470 (Direct) |
View |
2021-04-28 Exercise |
2021-04-29 6:05 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
800 | $1.86 | 116,471 (Direct) |
View |
2021-04-28 Exercise |
2021-04-29 6:05 pm |
N/A 2029-09-30 |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
800 | $0 | 116,471 (Direct) |
View |
2021-04-12 Exercise |
2021-04-13 5:20 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
1,200 | $1.86 | 117,271 (Direct) |
View |
2021-04-12 Exercise |
2021-04-13 5:20 pm |
N/A 2029-09-30 |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
1,200 | $0 | 117,271 (Direct) |
View |
2021-04-12 Exercise |
2021-04-13 5:19 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Beaurang Pierre Chief Business Officer |
2,396 | $0.84 | 157,558 (Direct) |
View |
2021-04-12 Exercise |
2021-04-13 5:19 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Beaurang Pierre Chief Business Officer |
5,104 | $1.11 | 157,558 (Direct) |
View |
2021-04-12 Exercise |
2021-04-13 5:19 pm |
N/A 2026-01-27 |
Nurix Therapeutics Inc. | NRIX | Beaurang Pierre Chief Business Officer |
7,500 | $0 | 157,558 (Direct) |
View |
2021-04-05 Exercise |
2021-04-06 4:04 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
400 | $7.26 | 87,270 (Direct) |
View |
2021-04-05 Exercise |
2021-04-06 4:04 pm |
N/A 2030-02-26 |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
400 | $0 | 87,270 (Direct) |
View |
2021-04-01 Exercise |
2021-04-02 5:22 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
400 | $7.26 | 87,670 (Direct) |
View |
2021-04-01 Exercise |
2021-04-02 5:22 pm |
N/A 2030-02-26 |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
400 | $0 | 87,670 (Direct) |
View |